10.1007/BF01241034 29
Even for those who qualify, getting a consistent supply can be a challenge
Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist
Your healthcare provider will need this information to determine if Contrave or phentermine is compatible with the other medications you take
However, this is a signal that is not present with either semaglutide or tirzepatide
Frequently Asked Questions As of July 2026, retatrutide has completed four Phase 3 readouts: TRIUMPH-4 (28.7% weight loss in knee OA population, December 2025), TRIUMPH-1 (28.3% weight loss in 2,339 general obesity patients, May 2026), TRANSCEND-T2D-1 (-2.0% HbA1c and 16.8% weight loss in 537 T2D patients, June 2026), and the TRIUMPH-1 sleep apnea substudy (60.6% AHI reduction, June 2026)